6CM
ALPN

683 Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

683 Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-23,493
Closed -$296K – 245
2020
Q4 		$296K Buy
+23,493
New +$231K 0.01% 186

Other funds holding ALPN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

683 Capital Management's ALPN Position: Q1 2021 in Review

683 Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2021, closing a stake of 23,493 shares — an estimated $296K sold.

683 Capital Management first reported a position in ALPN in Q4 2020 and held it in 1 quarter. The position peaked at $296K in Q4 2020. 48 funds tracked by Wall St. Rank hold ALPN as of Q1 2021.

  • 683 Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q1 2021 after selling out during the quarter.
  • 683 Capital Management sold 23,493 Alpine Immune Sciences Inc shares in Q1 2021, an estimated $296K.
  • 683 Capital Management first reported a position in Alpine Immune Sciences Inc in Q4 2020 and held it in 1 quarter.
  • 683 Capital Management's Alpine Immune Sciences Inc position peaked at $296K in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.